Starpharma Holdings Limited (SPL.AX) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-06-30. SPL.AX files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.16% | 30.00% | Pass |
| Interest-bearing investments | 4.10% | 30.00% | Pass |
| Non-permissible income | 19.10% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 17.15% | 33.00% | Pass |
| Interest-bearing investments | 60.61% | 33.00% | Fail |
| Non-liquid assets | 23.51% | at least 20.00% | Pass |
| Non-permissible income | 19.10% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 17.15% | 33.33% | Pass |
| Cash + interest-bearing securities | 60.61% | 33.33% | Fail |
| Accounts receivable | 76.49% | 33.33% | Fail |
| Non-permissible income | 19.10% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 17.15% | 33.33% | Pass |
| Cash + interest-bearing securities | 60.61% | 33.33% | Fail |
| Accounts receivable | 76.49% | 50.00% | Fail |
| Non-permissible income | 19.10% | 5.00% | Fail |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.65% | 33.00% | Pass |
| Cash + interest-bearing securities | 9.37% | 33.00% | Pass |
| Accounts receivable | 2.46% | 33.00% | Pass |
| Non-permissible income | 19.10% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.32% | 33.00% | Pass |
| Cash + interest-bearing securities | 11.72% | 49.00% | Pass |
| Accounts receivable | 3.07% | 49.00% | Pass |
| Non-permissible income | 19.10% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.32% | 33.33% | Pass |
| Cash + interest-bearing securities | 11.72% | 33.33% | Pass |
| Accounts receivable | 14.79% | 49.00% | Pass |
| Non-permissible income | 19.10% | 5.00% | Fail |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 42.00 | NEUTRAL |
| Stochastic %K (14) | 7.41 | BUY |
| CCI (20) | -34.01 | NEUTRAL |
| Williams %R (14) | -92.59 | BUY |
| MACD (12,26,9) | 0.00 | BUY |
| ROC (10) | -1.40 | SELL |
| Momentum (10) | -0.01 | SELL |
| EMA (10) | 0.76 | SELL |
| SMA (10) | 0.76 | SELL |
| EMA (20) | 0.75 | SELL |
| SMA (20) | 0.74 | SELL |
| EMA (30) | 0.74 | SELL |
| SMA (30) | 0.75 | SELL |
| EMA (50) | 0.73 | SELL |
| SMA (50) | 0.73 | SELL |
| EMA (100) | 0.69 | BUY |
| SMA (100) | 0.71 | SELL |
| EMA (200) | 0.57 | BUY |
| SMA (200) | 0.57 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; DEP technology for antibody-drug conjugates; and SPL7013 for vaginal gel, a treatment of bacterial vaginosis and prevention of recurrent BV, and an antiviral condom. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is based in Abbotsford, Australia.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.